We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Name | Symbol | Market | Type |
|---|---|---|---|
| Astellas Pharma Inc (PK) | USOTC:ALPMY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.01 | 0.10% | 9.55 | 9.47 | 9.59 | 9.59 | 9.53 | 9.54 | 452,047 | 21:06:02 |
From Oct 2023 to Apr 2024
By Stephen Nakrosis
Astellas Pharma and Seagen said the Food and Drug Administration has accepted for priority review a supplemental biologics license application for Padcev in combination with Keytruda to treat certain adult patients with bladder cancer.
The combination therapy of Padcev, or enfortumab vedotin-ejfv, and Keytruda is being studied as a treatment for adult patients with locally advanced or metastatic urothelial cancer, the companies said. Keytruda, an immunotherapy marketed by Merck, works with the body's immune system to help fight cancer, the company said Thursday.
Results from a pivotal confirmatory trial found the combination "significantly extended overall survival and progression-free survival versus standard platinum containing chemotherapy," according to Astellas.
It is estimated that 82,290 people will be diagnosed with bladder cancer in the U.S. this year, according to the companies.
Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 30, 2023 17:49 ET (22:49 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Astellas Pharma (PK) Chart |
1 Month Astellas Pharma (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
